| Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival S Dudani, G De Velasco, JC Wells, CL Gan, F Donskov, C Porta, ... JAMA network open 4 (1), e2021869-e2021869, 2021 | 162 | 2021 |
| Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma Z Bakouny, DA Braun, SA Shukla, W Pan, X Gao, Y Hou, A Flaifel, S Tang, ... Nature communications 12 (1), 808, 2021 | 110 | 2021 |
| First-line immuno-oncology combination therapies in metastatic renal-cell carcinoma: results from the international metastatic renal-cell carcinoma database consortium S Dudani, J Graham, JC Wells, Z Bakouny, SK Pal, N Dizman, F Donskov, ... European urology 76 (6), 861-867, 2019 | 79 | 2019 |
| Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma S Abou Alaiwi, W Xie, AH Nassar, S Dudani, D Martini, Z Bakouny, ... Journal for ImmunoTherapy of Cancer 8 (1), 2020 | 75 | 2020 |
| Upfront cytoreductive nephrectomy for metastatic renal cell carcinoma treated with immune checkpoint inhibitors or targeted therapy: an observational study from the … Z Bakouny, T El Zarif, S Dudani, JC Wells, CL Gan, F Donskov, J Shapiro, ... European urology 83 (2), 145-151, 2023 | 72 | 2023 |
| Prognostication in kidney cancer: recent advances and future directions J Graham, S Dudani, DYC Heng Journal of Clinical Oncology 36 (36), 3567-3573, 2018 | 70 | 2018 |
| Integrative clinical and molecular characterization of translocation renal cell carcinoma Z Bakouny, A Sadagopan, P Ravi, NY Metaferia, J Li, S AbuHammad, ... Cell reports 38 (1), 2022 | 65 | 2022 |
| Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant … S Dudani, H Marginean, PA Tang, JG Monzon, S Raissouni, TR Asmis, ... BMC cancer 19, 1-9, 2019 | 55 | 2019 |
| Optimal management of leptomeningeal carcinomatosis in breast cancer patients—a systematic review S Dudani, S Mazzarello, J Hilton, B Hutton, L Vandermeer, R Fernandes, ... Clinical Breast Cancer 16 (6), 456-470, 2016 | 35 | 2016 |
| Point of care molecular testing: community-based rapid next-generation sequencing to support cancer care BS Sheffield, A Beharry, J Diep, K Perdrizet, MAJ Iafolla, W Raskin, ... Current Oncology 29 (3), 1326-1334, 2022 | 32 | 2022 |
| An update on predictive biomarkers in metastatic renal cell carcinoma S Dudani, MF Savard, DYC Heng European Urology Focus 6 (1), 34-36, 2020 | 31 | 2020 |
| Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic … CL Gan, S Dudani, JC Wells, F Donskov, SK Pal, N Dizman, N Rathi, ... Cancer Medicine 10 (4), 1212-1221, 2021 | 30 | 2021 |
| Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials CL Gan, I Stukalin, DE Meyers, S Dudani, HAI Grosjean, S Dolter, ... European Journal of Cancer 151, 115-125, 2021 | 29 | 2021 |
| Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel–cyclophosphamide chemotherapy for breast cancer: a systematic review R Fernandes, S Mazzarello, C Stober, L Vandermeer, S Dudani, ... Breast cancer research and treatment 161, 1-10, 2017 | 28 | 2017 |
| Cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or targeted therapy (TT): a propensity score-based … Z Bakouny, W Xie, S Dudani, C Wells, CL Gan, F Donskov, J Shapiro, ... Journal of Clinical Oncology 38 (6_suppl), 608-608, 2020 | 24 | 2020 |
| Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy J Graham, JC Wells, S Dudani, CL Gan, F Donskov, J Lee, ... European Journal of Cancer 171, 124-132, 2022 | 23 | 2022 |
| Assessment of immune checkpoint inhibitors and genomic alterations by body mass index in advanced renal cell carcinoma AKA Lalani, Z Bakouny, S Farah, F Donskov, S Dudani, DYC Heng, ... JAMA oncology 7 (5), 773-775, 2021 | 22 | 2021 |
| An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma E Hasanov, DN Yeboa, MD Tucker, TA Swanson, TH Beckham, B Rini, ... CA: A Cancer Journal for Clinicians 72 (5), 454-489, 2022 | 21 | 2022 |
| Sites of Metastasis and Survival in Metastatic Renal-Cell Carcinoma (mRCC) S Dudani, J Guillermo de Velasco, CL Gan, F Donskov, C Porta, ... Europe 3474 (10,320), 34, 2020 | 21 | 2020 |
| Real‐world assessment of clinical outcomes among first‐line sunitinib patients with clear cell metastatic renal cell carcinoma (mRCC) by the international mRCC database … MF Savard, JC Wells, J Graham, S Dudani, JA Steinharter, BA McGregor, ... The Oncologist 25 (5), 422-430, 2020 | 18 | 2020 |
